Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large.
Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
PharmExec Blog
Follow Us
RSS
Bookstore
Putting the M Back in M&A